drugset
drugset / Trial / NCT04459871

Safety and Efficacy of Topical Recombinant Human Thrombin(rhThrombin) for Surgical Hemostasis

NCT04459871 ↗

Phase 3 Completed 348 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

A multicenter, stratified randomized, double-blind, placebo-controlled, phase 3 clinical trial.

Timeline

Start
2019-11-11
Primary completion
2021-10-20
Completion
2021-10-20

Drugs

EvaluationDrugModalityDoseRoute
Subject recombinant human Thrombin Protein / enzyme biologic 1000 unknown Topical

Indications

No indication recorded.